Aravive, Inc.

Informe acción NasdaqGS:ARAV

Capitalización de mercado: US$2.9m

Aravive Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Aravive's earnings have been declining at an average annual rate of -12.3%, while the Biotechs industry saw earnings growing at 17.8% annually. Revenues have been declining at an average rate of 6.2% per year.

Información clave

-12.3%

Tasa de crecimiento de los beneficios

29.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs 17.0%
Tasa de crecimiento de los ingresos-6.2%
Rentabilidad financiera-2,342.6%
Margen neto-569.7%
Última actualización de beneficios30 Sep 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Apr 26
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Sep 03
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Aravive Q2 GAAP EPS misses, revenue beats

Aug 11

Aravive appoints Robert Geller as CMO

Jul 05

We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

May 15
We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Nov 06
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Jun 25
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive EPS beats by $0.01, misses on revenue

May 06

Aravive shares rise after dosing first patient in late-stage ovarian cancer study

Apr 27

Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Mar 18
Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Feb 09
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive: Pipeline-In-A-Pill In Oncology

Dec 28

Aravive (ARAV) Investor Presentation - Slideshow

Dec 04

Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative

Nov 19

Aravive, 3D Medicine inks licensing pact for AVB-500 for Greater China

Nov 10

Desglose de ingresos y gastos

Cómo gana y gasta dinero Aravive. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

NasdaqGS:ARAV Ingresos, gastos y beneficios (USD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
30 Sep 237-40130
30 Jun 239-77130
31 Mar 2310-113130
31 Dec 229-76130
30 Sep 229-60120
30 Jun 226-56120
31 Mar 228-44110
31 Dec 217-39110
30 Sep 2112-30110
30 Jun 2110-30110
31 Mar 216-28110
31 Dec 206-31130
30 Sep 200-31130
30 Jun 200-26130
31 Mar 203-24130
31 Dec 195-18140
30 Sep 196-65210
30 Jun 196-65230
31 Mar 193-72250
31 Dec 181-76260
30 Sep 1840623-93
30 Jun 1840-3725-51
31 Mar 1840-6426-22
31 Dec 1740-85290
30 Sep 170-13828110
30 Jun 170-1162888
31 Mar 170-1012676
31 Dec 160-962472
30 Sep 160-942171
30 Jun 160-872266
31 Mar 160-842161
31 Dec 150-822060
30 Sep 150-782256
30 Jun 150-711851
31 Mar 150-601645
31 Dec 140-831433
30 Sep 140-731224
30 Jun 140-64919
31 Mar 140-59616
31 Dec 130-18415

Ingresos de calidad: ARAV is currently unprofitable.

Margen de beneficios creciente: ARAV is currently unprofitable.


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: ARAV is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.

Acelerando crecimiento: Unable to compare ARAV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Beneficios vs. Industria: ARAV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).


Rentabilidad financiera

Alta ROE: ARAV has a negative Return on Equity (-2342.56%), as it is currently unprofitable.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado